Earl Martin, DO
Family Medicine · Tomball, TXNPI 1336295344
Payments from drug & device makers
Across 2,148 payments — averaging $2865.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2.4M
- Sanofi Pasteur Inc.$1.5M
- Emergent Biosolutions Inc.$1.4M
- Eli Lilly$755K
- AstraZeneca$27K
- Pfizer$27K
- plus $18K from 31 others
Across 8 payments — averaging $3358.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$27K
- Pfizer$330
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 96 | $2,374,125 |
| Sanofi Pasteur Inc. | 123 | $1,507,631 |
| Emergent Biosolutions Inc. | 1,485 | $1,446,522 |
| Eli Lilly | 35 | $755,212 |
| AstraZeneca | 21 | $27,014 |
| Pfizer | 30 | $26,763 |
| Amgen | 127 | $14,088 |
| AbbVie(2 entities) | 32 | $547 |
| Novo Nordisk | 36 | $537 |
| Lilly USA, LLC | 18 | $296 |
| Novartis | 16 | $268 |
| GSK | 15 | $247 |
| Aytu Biopharma, Inc. | 22 | $207 |
| Antares Pharma, Inc. | 12 | $207 |
| Radius Health, Inc. | 7 | $151 |
| Boehringer Ingelheim | 7 | $142 |
| Merck | 7 | $133 |
| Teva Pharmaceuticals USA, Inc. | 6 | $122 |
| Arbor Pharmaceuticals, Inc. | 8 | $115 |
| IBSA Pharma Inc. | 7 | $107 |
| Tolmar, Inc. | 5 | $87 |
| Abbott | 4 | $78 |
| Amarin Pharma, Inc. | 4 | $75 |
| Clarus Therapeutics Inc. | 5 | $67 |
| Acerus Pharmaceuticals Corporation | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Edwards Lifesciences | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Bausch Health US, LLC | 1 | $12 |
How this compares
$6,155,093 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Tomball
- Earl MartinTomball$30.1M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.